- Home
- AKRO vs GERN Comparison
AKRO vs GERN Comparison
Compare AKRO & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- GERN
- Stock Information
- Founded
- AKRO 2017
- GERN 1990
- Country
- AKRO United States
- GERN United States
- Employees
- AKRO N/A
- GERN N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- AKRO Health Care
- GERN Health Care
- Exchange
- AKRO Nasdaq
- GERN Nasdaq
- Market Cap
- AKRO 2.4B
- GERN 2.5B
- IPO Year
- AKRO 2019
- GERN 1996
- Fundamental
- Price
- AKRO $28.09
- GERN $3.66
- Analyst Decision
- AKRO Strong Buy
- GERN Strong Buy
- Analyst Count
- AKRO 7
- GERN 10
- Target Price
- AKRO $43.20
- GERN $6.95
- AVG Volume (30 Days)
- AKRO 617.2K
- GERN 9.5M
- Earning Date
- AKRO 11-08-2024
- GERN 11-07-2024
- Dividend Yield
- AKRO N/A
- GERN N/A
- EPS Growth
- AKRO N/A
- GERN N/A
- EPS
- AKRO N/A
- GERN N/A
- Revenue
- AKRO N/A
- GERN $29,480,000.00
- Revenue This Year
- AKRO N/A
- GERN $30,930.80
- Revenue Next Year
- AKRO N/A
- GERN $315.72
- P/E Ratio
- AKRO N/A
- GERN N/A
- Revenue Growth
- AKRO N/A
- GERN 9199.68
- 52 Week Low
- AKRO $14.41
- GERN $1.64
- 52 Week High
- AKRO $37.00
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- AKRO 38.58
- GERN 29.99
- Support Level
- AKRO $31.12
- GERN $3.98
- Resistance Level
- AKRO $35.11
- GERN $4.50
- Average True Range (ATR)
- AKRO 1.99
- GERN 0.21
- MACD
- AKRO -0.53
- GERN -0.05
- Stochastic Oscillator
- AKRO 11.68
- GERN 3.45
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.